CJC-1295
Also known as: Modified GRF(1-29), DAC:GRF
Long-acting GHRH analog that stimulates sustained growth hormone release.
Evidence
Moderate
FDA status
Not FDA-approved
Source
Synthetic GHRH analog
Overview
Long-acting GHRH analog that stimulates sustained growth hormone release.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, activates adenylyl cyclase/cAMP/PKA cascade, enhances GH gene transcription and protein synthesis, resists degradation for prolonged action (5.8-8.1 day half-life), raises GH and IGF-1 levels in small human studies.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Increases growth hormone and IGF-1 levels
- Enhances muscle growth and recovery
- Improves body composition
- Supports fat loss
- Better sleep quality
- Enhanced tissue repair
- Improved skin quality
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. CJC-1295 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Clinical trials in healthy adults, ongoing research
Small human studies showed raised GH and IGF-1 levels. Development stopped, and there are no long-term safety data. FDA has raised safety concerns about it.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Water retention
- •Increased hunger
- •Numbness/tingling
- •Fatigue
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
- Breastfeeding
Interactions
- ⚠May affect glucose metabolism
- ⚠Caution with insulin
Quick Facts
Related Peptides
Ipamorelin
Selective ghrelin mimetic that triggers rapid growth hormone release without affecting cortisol or prolactin.
Tesamorelin
Synthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy.
Sermorelin
Short-acting GHRH analog that stimulates natural pulsatile growth hormone release from the pituitary.